Fri, May 13, 2011
Thu, May 12, 2011
Wed, May 11, 2011
Tue, May 10, 2011
Mon, May 9, 2011
Sun, May 8, 2011
Sat, May 7, 2011
Fri, May 6, 2011
Thu, May 5, 2011
Wed, May 4, 2011
Tue, May 3, 2011
Mon, May 2, 2011
Fri, April 29, 2011
Thu, April 28, 2011
Wed, April 27, 2011
Tue, April 26, 2011
Mon, April 25, 2011
Fri, April 22, 2011
Thu, April 21, 2011
Wed, April 20, 2011
Tue, April 19, 2011
Mon, April 18, 2011

Theragenics to Report First Quarter 2011 Financial Results Thursday, May 5


//health-fitness.news-articles.net/content/2011/ .. arter-2011-financial-results-thursday-may-5.html
Published in Health and Fitness on Thursday, April 28th 2011 at 4:16 GMT by Market Wire   Print publication without navigation


BUFORD, Ga.--([ BUSINESS WIRE ])--Theragenics Corporation® (NYSE:TGX) expects to release first quarter 2011 financial results before the market opens on May 5, 2011. Following this release, the Company will host a conference call at 11:00 a.m. Eastern.

To participate in the call, dial 877-407-4019 or 201-689-8337. The call is also being webcast and can be accessed via Theragenicsa™ website, [ www.theragenics.com ]. A replay will be available on the website for one month. A phone replay will be available until Midnight, May 12, 2011 by dialing 877-660-6853 or 201-612-7415, and entering the account # 372 and conference ID 371625.

Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. Its surgical products business ([ www.cpmedical.com ], [ www.galtmedical.com ], [ www.needletech.com ]) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle based products. The surgical products segment serves a number of markets and applications, including, among others, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenicsa™ brachytherapy business manufactures, markets and distributes aseedsa used primarily in the minimally invasive treatment of localized prostate cancer. The Companya™s brachytherapy product line includes its palladium-103 TheraSeed® device ([ www.theraseed.com ]), and the iodine-125 based devices I-Seed and OncoSeeda".


Publication Contributing Sources